Tyg Oncology Ltd.
TYG Oncology is a biotech company specializing in novel cancer immunotherapies based on its proprietary S-TIR™ technology platform. The company aims to boost the immune system to generate strong, specific, and controlled responses against cancer, with a focus on active checkpoint control immunotherapy. Their lead product candidate, TYG100, targets gastroenterological cancers and has demonstrated significant immune response improvements in preclinical studies. TYG Oncology's therapies activate all four natural tumor-killing mechanisms of the immune system without side effects, targeting multiple cancer types.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Lead candidate: active immunotherapy targeting gastrin family peptides (preclinical)
A protein/peptide-based active immunotherapy candidate that targets gastrin-family circulating peptides to induce neutralizing antibodies and tumour-specific cellular responses for gastrointestinal cancers (developed on a modular APC-targeting platform).
Preclinical candidate: immunotherapy directed at HER2 ectodomain
A platform-based immunotherapy candidate directed against the ectodomain of HER2/neu intended to generate polyclonal humoral and cellular responses as an alternative to passive HER2-targeted therapies.
Lead candidate: active immunotherapy targeting gastrin family peptides (preclinical)
A protein/peptide-based active immunotherapy candidate that targets gastrin-family circulating peptides to induce neutralizing antibodies and tumour-specific cellular responses for gastrointestinal cancers (developed on a modular APC-targeting platform).
Preclinical candidate: immunotherapy directed at HER2 ectodomain
A platform-based immunotherapy candidate directed against the ectodomain of HER2/neu intended to generate polyclonal humoral and cellular responses as an alternative to passive HER2-targeted therapies.
Services
Licensing of lead preclinical immunotherapy candidates and access to the underlying immunotherapy platform for development and commercialization.
Licensing of lead preclinical immunotherapy candidates and access to the underlying immunotherapy platform for development and commercialization.
Expertise Areas
- Cancer immunotherapy platform engineering
- Antigen selection for circulating protein ligands
- Preclinical immunogenicity and safety testing
- Early-phase clinical trial design (first-in-human, Phase II planning)
Key Technologies
- Modular two-part immunotherapy architecture (APC-targeting + immunogen)
- Fc-gamma receptor-mediated APC targeting
- TLR9-mediated intrinsic adjuvant activation
- Designed dimerization motifs for module pairing
News & Updates
April 2014
Dr. Paul Broome presented the TYG100 technology at the AACR meeting, exceeding clinically relevant titres of gastrin neutralising antibodies in Phase 3 trials with no serious adverse events.
April 2016
TYG Oncology successfully manufactured reference material, funded partly by Cancer Research UK, marking a milestone in pancreatic cancer treatment using active checkpoint control immunotherapy.
March 2016
OncoQR announced preclinical dose-ranging findings for TYG100, with a single dose achieving clinical antibody levels in NHP and patients treated with gemcitabine, and expanded collaboration to tackle additional cancers.
February 2016
Experimental Cancer Medicines Centres in Leeds, Glasgow, and Belfast designed parallel first-in-human trials for TYG100.
November 2014
TYG Oncology filed for patent protection of TYG100.
April 2014
Dr. Paul Broome presented the TYG100 technology at the AACR meeting, exceeding clinically relevant titres of gastrin neutralising antibodies in Phase 3 trials with no serious adverse events.
April 2016
TYG Oncology successfully manufactured reference material, funded partly by Cancer Research UK, marking a milestone in pancreatic cancer treatment using active checkpoint control immunotherapy.
March 2016
OncoQR announced preclinical dose-ranging findings for TYG100, with a single dose achieving clinical antibody levels in NHP and patients treated with gemcitabine, and expanded collaboration to tackle additional cancers.
February 2016
Experimental Cancer Medicines Centres in Leeds, Glasgow, and Belfast designed parallel first-in-human trials for TYG100.
November 2014
TYG Oncology filed for patent protection of TYG100.